Wednesday, August 14, 2024
11:06 AM EST – MediPharm Labs Corp. : Announced its financial results for the three months ended June 30, 2024. Adjusted EBITDA proved negative $124K in Q2 2024, significantly improved from negative $949K during the three months ended March 31, 2024, and representing 96% growth versus Adjusted EBITDA for the same quarter in 2023. MediPharm Labs Corp. (T.LABS ) shares were unchanged at 0.07.
Stocks in Play: MediPharm Labs Corp., Wed, 14 Aug 2024 11:12:06 EST